This article first appeared on GuruFocus.

Taysha Gene Therapies Inc (NASDAQ:TSHA) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $1.38 million, and the earnings are expected to come in at -$0.09 per share. The full year 2025's revenue is expected to be $7.52 million, and the earnings are expected to be -$0.35 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 4 Warning Sign with GO.

Is TSHA fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Taysha Gene Therapies Inc (NASDAQ:TSHA) have increased from $7.14 million to $7.52 million for the full year 2025 and declined from $4.53 million to $4.09 million for 2026 over the past 90 days. Earnings estimates have declined from -$0.33 per share to -$0.35 per share for the full year 2025 and declined from -$0.38 per share to -$0.40 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Taysha Gene Therapies Inc's (NASDAQ:TSHA) actual revenue was $1.99 million, which beat analysts' revenue expectations of $1.61 million by 23.74%. Taysha Gene Therapies Inc's (NASDAQ:TSHA) actual earnings were -$0.09 per share, which missed analysts' earnings expectations of -$0.08 per share by -9.76%. After releasing the results, Taysha Gene Therapies Inc (NASDAQ:TSHA) was up by 5.43% in one day.

Based on the one-year price targets offered by 13 analysts, the average target price for Taysha Gene Therapies Inc (NASDAQ:TSHA) is $9.77 with a high estimate of $14.00 and a low estimate of $5.00. The average target implies an upside of 96.96% from the current price of $4.96.

Based on GuruFocus estimates, the estimated GF Value for Taysha Gene Therapies Inc (NASDAQ:TSHA) in one year is $0.00, suggesting a downside of -100% from the current price of $4.96.

Based on the consensus recommendation from 13 brokerage firms, Taysha Gene Therapies Inc's (NASDAQ:TSHA) average brokerage recommendation is currently 1.7, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.